Skip to main content

Argenx SE 6-K, filed Nov 9, 2026

Argenx SE (ARGX)

6-K 2026-11-09 For: 2026-11-09
View Original
Added on November 09, 2026

About this 6-K

Argenx SE filed this 6-K on November 9, 2026.

argenx said the Phase 3 ALKIVIA study of efgartigimod met primary and key secondary endpoints in combined IMNM and DM populations; it plans to submit an sBLA for IMNM by the end of 2026. AI summary